News

Nintedanib and docetaxel provide small PFS advantage in NSCLC

View on the News

Data lacking for 14% of study group

The progression-free survival analysis was performed in 1,134 (86%) of the 1,314 patients randomized, because the PFS data cutoff occurred 3 months before the actual completion of trial accrual. Also, there was a 2-year gap between the final PFS analysis and the overall survival analysis.

Although the study was reported as being positive, the lack of PFS data on 14% of the population precluded a full intention-to-treat analysis. It would be interesting to see whether the survival benefit with nintedanib in patients with adenocarcinomas would remain if this subgroup of patients were further stratified by prior bevacizumab exposure. Further, the apparent advantage for the combination in patients with platinum-refractory adenocarcinomas needs to be validated in larger studies.

Dr. Benjamin Besse is a thoracic oncologist at the Institut Gustave-Roussy in Villejuif, France. Dr. Besse, who was the invited discussant of the study, reported serving as an uncompensated advisor to Boehringer-Ingelheim.


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO – A combination of docetaxel and nintedanib, a novel inhibitor of multiple tumor growth factors, was associated with a small but significant improvement in progression-free survival in patients with advanced non–small cell lung cancer as compared with docetaxel alone.

In the phase III LUME-Lung I trial in patients with previously treated stage IIIB/IV or recurrent non–-small cell lung cancer (NSCLC), median progression-free survival (PFS) was 3.4 months for patients randomized to nintedanib and docetaxel, compared with 2.7 months for patients assigned to placebo and docetaxel (hazard ratio, 0.79; P = .0019), reported Dr. Martin Reck of the department of thoracic oncology at Hospital Grosshansdorf, Germany.

In addition, "we have seen a significant improvement of overall survival in patients with adenocarcinoma," Dr. Reck said at the annual meeting of the American Society of Clinical Oncology.

However, when patients with squamous cell NSCLC were included in the analysis, there was no significant difference in overall survival between the treatment groups, he said.

Nintedanib is an oral kinase inhibitor that targets vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-3, platelet-derived growth factor receptors alpha and beta, and the RET tyrosine kinase.

In clinical trials, nintedanib has been delivered safely in combination with various chemotherapy agents, including docetaxel, paclitaxel, platinum comp2ounds, and gemcitabine, and as a single agent had clinical activity in a phase II trial against recurrent NSCLC.

Dr. Reck and his colleagues enrolled 1,314 patients with stage IIIB or IV or recurrent NSCLC after first-line chemotherapy and randomly assigned them in a double-blinded fashion to receive intravenous docetaxel 75 mg/m2 on day 1 of a 21-day cycle plus either oral nintedanib 200 mg or placebo twice daily on days 2 through 21 of each cycle. The number of potential docetaxel cycles was unlimited, and docetaxel monotherapy could continue after four cycles of the combination at the investigator’s discretion.

Patients were stratified by performance status, prior bevacizumab (Avastin) use, squamous or nonsquamous histology, and presence or absence of brain metastases.

As of the February 2013 data cutoff, 6 of the 652 patients assigned to the combination and 6 of the 655 assigned to docetaxel/placebo remained on study.

In the intention-to-treat analysis, the trial met its primary endpoint of a centrally reviewed PFS advantage for the combination.

PFS was significantly better both in patients with adenocarcinoma histologies treated with the combination (median 4.0 vs. 2.8 months; HR, 0.77; P = .0193) and with squamous cell carcinomas (2.9 vs. 2.6 months; HR, 0.77; P = .02).

Overall survival did not differ, at a median of 10.1 vs. 9.1 month. Among patients with adenocarcinomas, however, survival was significantly better, at a median of 12.6 vs. 10.3 months, respectively (HR, 0.82; P = .0359). There was also a hint of benefit in patients with adenocarcinomas refractory to prior chemotherapy with a platinum compound (median overall survival, 9.8 vs. 6.3 months; HR, 0.62; P = .0246), although this subanalysis included only 107 patients.

The combination was no better than docetaxel and placebo among patients with squamous cell cancers.

Grade 3 or greater adverse events occurred in 71% of patients on nintedanib/docetaxel, and 64% of controls. In each group, about 22% of patients had adverse events leading to discontinuation of therapy. The most common adverse events were bleeding, thromboembolic events, and hypertension, each of which occurred more frequently with the combination than with docetaxel alone.

The LUME-Lung 1 trial was sponsored by Boehringer Ingelheim. Dr. Reck disclosed serving as an advisor and lecturer for Hoffman-La Roche, Lilly, AstraZeneca, Pfizer, Bristol-Myers Squibb, and Daiichi-Sankyo.

Recommended Reading

Standard-dose radiation bests high-dose radiation in advanced NSCLC
MDedge Hematology and Oncology
Ultralow-dose CT bests X-Ray for lung cancer follow-up, but is it enough?
MDedge Hematology and Oncology
Real-world NLST results show CT scans find more early-stage lung cancers
MDedge Hematology and Oncology
CDC urges doctors to help patients quit smoking
MDedge Hematology and Oncology
Survival equivalent with sublobar, lobar resection of stage Ia NSCLC
MDedge Hematology and Oncology
Treating refractory and metastatic lung cancer
MDedge Hematology and Oncology
Ganetespib trial hints at survival benefit in lung adenocarcinoma
MDedge Hematology and Oncology
VeriStrat predicts second-line treatment response in advanced lung cancer
MDedge Hematology and Oncology
Wedge resection in NSCLC: Is 15 mm the magic margin?
MDedge Hematology and Oncology
START trial keeps L-BLP25 immunotherapy alive in stage III NSCLC
MDedge Hematology and Oncology